Skip to content

A Multicenter, Self-Matched Positive Controlled Clinical Trial Protocol of Continuous Glucose Monitoring System for the Efficacy and Safety of Real-Time Monitoring of Glucose Concentration in Subcutaneous Tissue Fluid in Patients with Diabetes

A Multicenter, Self-Matched Positive Controlled Clinical Trial Protocol of Continuous Glucose Monitoring System for the Efficacy and Safety of Real-Time Monitoring of Glucose Concentration in Subcutaneous Tissue Fluid in Patients with Diabetes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092405
Enrollment
Unknown
Registered
2024-11-15
Start date
2024-01-24
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Group of diabetes (Continuously wear the study medical device for 15 days):No intervention

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients diagnosed with diabetes. (1) Age 18 and above, regardless of gender, with stable vital signs. (2) Forearm can establish a venous blood collection pathway. (3) Hematocrit/hematocrit = 70%. (4) Voluntarily participate in this experiment and sign an informed consent form. (5) Good compliance and ability to cooperate in completing the entire clinical trial.

Exclusion criteria

Exclusion criteria: (1) Wearing areas such as the upper arm and abdomen may have skin damage, scars, redness, swelling, or infection. (2) Individuals who are allergic to alcohol disinfectants or medical tape. (3) Individuals with hematological disorders that affect coagulation function or have been diagnosed with bleeding tendencies. (4) Pregnant and lactating women. (5) Individuals with mental disorders, cognitive and communication impairments, or those with high levels of mental stress who are not compatible with the author. (6) Wearing area with swollen skin. (7) Wearing a device that plans to undergo magnetic resonance imaging (MRI), computed tomography (CT), or X-ray examination within 15 days. (8) Individuals who have participated in clinical trials of drugs or devices within one month. (9) The researchers believe that it is not suitable for participants in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Consistency within the error range of the reference value with the control group; Proportion of Zone A+B of Clarke error grid; Proportion of Zone A+B of Consensus error grid; Mean absolute relative difference;

Secondary

MeasureTime frame
Accordance rate ;Sensor stability;Repeatability of sensors;Product usability questionnaire;Sensor life;Blood glucose data evaluation;Trend accuracy evaluation;

Countries

China

Contacts

Public ContactYang Tao

The First Affiliated Hospital of Nanjing Medical University

Yangt@njmu.edu.cn+86 25 8330 6466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026